$0.01
2.00% yesterday
Nasdaq, Nov 15, 09:52 pm CET
ISIN
US30048L1044
Symbol
EVFM
Sector
Industry

Evofem Biosciences, Inc. Stock price

$0.01
+0.00 3.16% 1M
-0.01 36.77% 6M
-0.05 84.69% YTD
-0.06 86.00% 1Y
-1,246.87 100.00% 3Y
-10,181.24 100.00% 5Y
-134,999.99 100.00% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.00 2.00%
ISIN
US30048L1044
Symbol
EVFM
Sector
Industry

Key metrics

Market capitalization $980.00k
P/E (TTM) P/E ratio negative
P/S ratio (TTM) P/S ratio 0.06
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 26.09%
Revenue (TTM) Revenue $17.10m
EBIT (operating result TTM) EBIT $-10.05m
Cash position $690.00k
EPS (TTM) EPS $-0.91
Short interest 11.01%
Show more

Is Evofem Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Evofem Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Evofem Biosciences, Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Evofem Biosciences, Inc.:

Buy
100%

Financial data from Evofem Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
17 17
26% 26%
100%
- Direct Costs - -
-
-
14 14
197% 197%
81%
- Selling and Administrative Expenses - -
-
-
- Research and Development Expense 2.54 2.54
13% 13%
15%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -10 -10
62% 62%
-59%
Net Profit -7.94 -7.94
117% 117%
-46%

In millions USD.

Don't miss a Thing! We will send you all news about Evofem Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evofem Biosciences, Inc. Stock News

Neutral
PRNewsWire
one day ago
— Improved loss from operations by 31% — — Acquired SOLOSEC, a commercially attractive, single-dose oral antibiotic FDA-approved to treat two pervasive sexual health infections   — — Forged commercial agreement for Phexxi in Middle East — SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB: EVFM) today announced financia...
Neutral
PRNewsWire
10 days ago
SAN DIEGO , Nov. 6, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem" or the "Company") today announced it has secured voting agreements with certain of its Series E-1 stockholders and convertible noteholders to ensure they will vote in favor of the proposed merger with Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt") subsidiary Adifem, Inc., under the Amended and Restated Merger Agre...
Neutral
PRNewsWire
3 months ago
SAN DIEGO , Aug. 20, 2024 /PRNewswire/ -- As the popularity of GLP-1 receptor agonists continues to surge in the treatment of obesity and type 2 diabetes, Evofem Biosciences, Inc. (OTCQB: EVFM) is raising awareness of the potential impact these medications may have on the effectiveness of oral contraceptives. With an increasing number of women turning to GLP-1 medications for weight management ...
More Evofem Biosciences, Inc. News

Company Profile

Evofem Biosciences, Inc. develops therapeutic solutions to meet sexual and reproductive health needs of women. Its product include Amphora Contraceptive for the prevention of pregnancy, antimicrobial drug product for the prevention of sexually transmitted infections and Antimicrobial Drug product to prevent the reoccurrence of bacterial vaginosis. The company was founded in 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Saundra Pelletier
Employees 37
Founded 2007
Website www.evofem.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today